An examination of anxiety and its influence on health-related quality of life in Parkinson's disease using the geriatric anxiety scale: a cross-sectional study.
Anxiety
Depression, older adults
Parkinson´s disease
Quality of life
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
received:
25
09
2023
accepted:
21
03
2024
medline:
29
3
2024
pubmed:
29
3
2024
entrez:
29
3
2024
Statut:
epublish
Résumé
Anxiety is one of the most common but often overlooked mood-related nonmotor symptoms in people with Parkinson's disease (PD). To improve the well-being of people with PD, it is important to understand the impact of anxiety in PD, especially its association with depressive and motor symptoms and its impact on health-related quality of life (HRQoL). 91 people with PD were assessed between June 2017 and June 2018. Anxiety was measured using the Geriatric Anxiety Scale (GAS) and its cognitive, somatic, and affective subscales. HRQoL was assessed using the Parkinson's Disease Questionnaire 39 (PDQ-39). Moreover, sociodemographic information, depressive symptoms, cognition, motor and nonmotor symptoms were assessed. Descriptive statistics, regression analyses, and path analyses were performed to understand predictors of anxiety and its influence on HRQoL. Of the 91 people with PD, 35 (38.5%) experienced anxiety. Anxiety symptoms in these individuals primarily manifest as somatic sensations. Anxiety, motor, and depressive symptoms are interlinked but contribute individually to HRQoL. Beyond motor symptoms, cognitive and affective aspects of anxiety impact HRQoL. While anxiety and depression overlap, the somatic and cognitive aspects of anxiety play a significant role in determining HRQoL in addition to depressive symptoms. Our study used the GAS and its three subscales to shed light on the connections between anxiety, depression, and motor impairment in people with PD. Although anxiety is linked to depression and motor symptoms, it independently affects the HRQoL of people with PD. Thus, it is crucial to adopt a comprehensive diagnostic approach that detects and considers the impact of anxiety on HRQoL in PD.
Sections du résumé
BACKGROUND
BACKGROUND
Anxiety is one of the most common but often overlooked mood-related nonmotor symptoms in people with Parkinson's disease (PD). To improve the well-being of people with PD, it is important to understand the impact of anxiety in PD, especially its association with depressive and motor symptoms and its impact on health-related quality of life (HRQoL).
METHODS
METHODS
91 people with PD were assessed between June 2017 and June 2018. Anxiety was measured using the Geriatric Anxiety Scale (GAS) and its cognitive, somatic, and affective subscales. HRQoL was assessed using the Parkinson's Disease Questionnaire 39 (PDQ-39). Moreover, sociodemographic information, depressive symptoms, cognition, motor and nonmotor symptoms were assessed. Descriptive statistics, regression analyses, and path analyses were performed to understand predictors of anxiety and its influence on HRQoL.
RESULTS
RESULTS
Of the 91 people with PD, 35 (38.5%) experienced anxiety. Anxiety symptoms in these individuals primarily manifest as somatic sensations. Anxiety, motor, and depressive symptoms are interlinked but contribute individually to HRQoL. Beyond motor symptoms, cognitive and affective aspects of anxiety impact HRQoL. While anxiety and depression overlap, the somatic and cognitive aspects of anxiety play a significant role in determining HRQoL in addition to depressive symptoms.
CONCLUSION
CONCLUSIONS
Our study used the GAS and its three subscales to shed light on the connections between anxiety, depression, and motor impairment in people with PD. Although anxiety is linked to depression and motor symptoms, it independently affects the HRQoL of people with PD. Thus, it is crucial to adopt a comprehensive diagnostic approach that detects and considers the impact of anxiety on HRQoL in PD.
Identifiants
pubmed: 38549058
doi: 10.1186/s12877-024-04911-8
pii: 10.1186/s12877-024-04911-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
298Informations de copyright
© 2024. The Author(s).
Références
Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s Disease in 204 Countries/Territories from 1990 to 2019. Front Public Health. 2021;9:776847. https://doi.org/10.3389/fpubh.2021.776847
doi: 10.3389/fpubh.2021.776847
pubmed: 34950630
pmcid: 8688697
Titova N, Qamar MA, Chaudhuri KR. The Nonmotor features of Parkinson’s Disease. Int Rev Neurobiol. 2017;132:33–54. https://doi.org/10.1016/bs.irn.2017.02.016
doi: 10.1016/bs.irn.2017.02.016
pubmed: 28554413
Balestrino R, Martinez-Martin P. Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease. J Neurol Sci. 2017;373:173–8. https://doi.org/10.1016/j.jns.2016.12.060
doi: 10.1016/j.jns.2016.12.060
pubmed: 28131182
Broen MPG, Narayen NE, Kuijf ML, Dissanayaka NNW, Leentjens AFG. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2016;31:1125–33. https://doi.org/10.1002/mds.26643
doi: 10.1002/mds.26643
pubmed: 27125963
Kwok JYY, Auyeung M, Chan HYL. Examining factors related to Health-related quality of life in people with Parkinson’s Disease. Rehabil Nurs. 2020;45:122–30. https://doi.org/10.1097/rnj.0000000000000179
doi: 10.1097/rnj.0000000000000179
pubmed: 30005001
Blundell EK, Grover LE, Stott J, Schrag A. The experience of anxiety for people with Parkinson’s disease. Npj Parkinsons Dis. 2023;9:1–9. https://doi.org/10.1038/s41531-023-00512-1
doi: 10.1038/s41531-023-00512-1
Hanna KK, Cronin-Golomb A. Impact of anxiety on quality of life in Parkinson’s disease. Parkinsons Dis. 2012;2012:640707. https://doi.org/10.1155/2012/640707
doi: 10.1155/2012/640707
pubmed: 22191074
D’Iorio A, Vitale C, Piscopo F, Baiano C, Falanga AP, Longo K, et al. Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson’s disease. Parkinsonism Relat Disord. 2017;43:114–7. https://doi.org/10.1016/j.parkreldis.2017.08.003
doi: 10.1016/j.parkreldis.2017.08.003
pubmed: 28797564
Todorova A, Jenner P, Chaudhuri KR. Non-motor Parkinson’s: integral to motor Parkinson’s, yet often neglected. Pract Neurol. 2014;14:310–22. https://doi.org/10.1136/practneurol-2013-000741
doi: 10.1136/practneurol-2013-000741
pubmed: 24699931
pmcid: 4174166
Dissanayaka NNW, O’Sullivan JD, Pachana NA, Marsh R, Silburn PA, White EX, et al. Disease-specific anxiety symptomatology in Parkinson’s disease. Int Psychogeriatr. 2016;28:1153–63. https://doi.org/10.1017/S1041610215002410
doi: 10.1017/S1041610215002410
pubmed: 26861614
Reynolds CF 3rd, Jeste DV, Sachdev PS, Blazer DG. Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry. 2022;21:336–63. https://doi.org/10.1002/wps.20996
doi: 10.1002/wps.20996
pubmed: 36073714
pmcid: 9453913
Pontone GM, Perepezko KM, Hinkle JT, Gallo JJ, Grill S, Leoutsakos J-M, et al. Anxious fluctuators a subgroup of Parkinson’s disease with high anxiety and problematic on-off fluctuations. Parkinsonism Relat Disord. 2022;105:62–8. https://doi.org/10.1016/j.parkreldis.2022.11.002
doi: 10.1016/j.parkreldis.2022.11.002
pubmed: 36371868
pmcid: 9722648
Leentjens AFG, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Anxiety rating scales in Parkinson’s disease: Critique and recommendations. Mov Disord. 2008;23:2015–25. https://doi.org/10.1002/mds.22233
doi: 10.1002/mds.22233
pubmed: 18792121
Abou Kassm S, Naja W, Haddad R, Pelissolo A. The relationship between anxiety disorders and Parkinson’s Disease: clinical and therapeutic issues. Curr Psychiatry Rep. 2021;23:20. https://doi.org/10.1007/s11920-021-01229-9
doi: 10.1007/s11920-021-01229-9
pubmed: 33660146
Pontone GM, Dissanayaka N, Apostolova L, Brown RG, Dobkin R, Dujardin K, et al. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease. NPJ Parkinsons Dis. 2019;5:30. https://doi.org/10.1038/s41531-019-0102-8
doi: 10.1038/s41531-019-0102-8
pubmed: 31840044
pmcid: 6906437
Dissanayaka NNW, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ, et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord. 2010;25:838–45. https://doi.org/10.1002/mds.22833
doi: 10.1002/mds.22833
pubmed: 20461800
Leentjens AFG, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord. 2011;26:484–92. https://doi.org/10.1002/mds.23528
doi: 10.1002/mds.23528
pubmed: 21312281
Therrien Z, Hunsley J. Assessment of anxiety in older adults: a systematic review of commonly used measures. Aging Ment Health. 2012;16:1–16. https://doi.org/10.1080/13607863.2011.602960
doi: 10.1080/13607863.2011.602960
pubmed: 21838650
Rutten S, Ghielen I, Vriend C, Hoogendoorn AW, Berendse HW, Leentjens AFG, et al. Anxiety in Parkinson’s disease: symptom dimensions and overlap with depression and autonomic failure. Parkinsonism Relat Disord. 2015;21:189–93. https://doi.org/10.1016/j.parkreldis.2014.11.019
doi: 10.1016/j.parkreldis.2014.11.019
pubmed: 25557888
Landau S, Harris V, Burn DJ, Hindle JV, Hurt CS, Samuel M, et al. Anxiety and anxious-depression in Parkinson’s disease over a 4-year period: a latent transition analysis. Psychol Med. 2016;46:657–67. https://doi.org/10.1017/S0033291715002196
doi: 10.1017/S0033291715002196
pubmed: 26492977
Leentjens AFG, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P. Anxiety rating scales in Parkinson’s disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Mov Disord. 2011;26:407–15. https://doi.org/10.1002/mds.23184
doi: 10.1002/mds.23184
pubmed: 21384425
Leentjens AFG, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson anxiety scale (PAS): development and validation of a new anxiety scale. Mov Disord. 2014;29:1035–43. https://doi.org/10.1002/mds.25919
doi: 10.1002/mds.25919
pubmed: 24862344
Segal DL, Granier KL, Pifer MA, Stone LE. Geriatric anxiety scale. In: Gu D, Dupre ME, editors. Encyclopedia of Gerontology and Population Aging. Cham: Springer International Publishing; 2019. pp. 1–7. https://doi.org/10.1007/978-3-319-69892-2_1103-1
doi: 10.1007/978-3-319-69892-2_1103-1
Gottschling J, Segal DL, Häusele C, Spinath FM, Stoll G. Assessment of anxiety in older adults: translation and psychometric evaluation of the German version of the geriatric anxiety scale (GAS). J Psychopathol Behav Assess. 2016;38:136–48. https://doi.org/10.1007/s10862-015-9504-z
doi: 10.1007/s10862-015-9504-z
Heimrich KG, Prell T. Short- and long-term effect of Parkinson’s Disease Multimodal Complex Treatment. Brain Sci. 2021;11:1460. https://doi.org/10.3390/brainsci11111460
doi: 10.3390/brainsci11111460
pubmed: 34827459
pmcid: 8615811
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601. https://doi.org/10.1002/mds.26424
doi: 10.1002/mds.26424
pubmed: 26474316
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. https://doi.org/10.1016/0022-3956(75)90026-6
doi: 10.1016/0022-3956(75)90026-6
pubmed: 1202204
Witt K, Granert O, Daniels C, Volkmann J, Falk D, van Eimeren T, et al. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson’s disease: results from a randomized trial. Brain. 2013;136:2109–19. https://doi.org/10.1093/brain/awt151
doi: 10.1093/brain/awt151
pubmed: 23801735
Segal DL, June A, Payne M, Coolidge FL, Yochim B. Development and initial validation of a self-report assessment tool for anxiety among older adults: the geriatric anxiety scale. J Anxiety Disord. 2010;24:709–14. https://doi.org/10.1016/j.janxdis.2010.05.002
doi: 10.1016/j.janxdis.2010.05.002
pubmed: 20558032
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26:353–7. https://doi.org/10.1093/ageing/26.5.353
doi: 10.1093/ageing/26.5.353
pubmed: 9351479
Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22:41–7. https://doi.org/10.1002/mds.21198
doi: 10.1002/mds.21198
pubmed: 17115387
Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord. 2012;18:54–8. https://doi.org/10.1016/j.parkreldis.2011.08.013
doi: 10.1016/j.parkreldis.2011.08.013
pubmed: 21917501
Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
Cohen J. Statistical Power Analysis for the behavioral sciences. 2nd ed. New York: Routledge; 1988. https://doi.org/10.4324/9780203771587
doi: 10.4324/9780203771587
Rosseel Y. lavaan: An R Package for Structural Equation Modeling. 2012 2012;48:36%J Journal of Statistical Software. https://doi.org/10.18637/jss.v048.i02
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). 2013.
Dissanayaka NNNW, White E, O’Sullivan JD, Marsh R, Pachana NA, Byrne GJ. The clinical spectrum of anxiety in Parkinson’s disease. Mov Disord. 2014;29:967–75. https://doi.org/10.1002/mds.25937
doi: 10.1002/mds.25937
pubmed: 25043800
Pachana NA, Egan SJ, Laidlaw K, Dissanayaka N, Byrne GJ, Brockman S, et al. Clinical issues in the treatment of anxiety and depression in older adults with Parkinson’s disease. Mov Disord. 2013;28:1930–4. https://doi.org/10.1002/mds.25689
doi: 10.1002/mds.25689
pubmed: 24123116
Hong C-T, Tan S, Huang T-W. Psychotherapy for the treatment of anxiety and depression in patients with Parkinson Disease: a Meta-analysis of Randomized controlled trials. J Am Med Dir Assoc. 2021;22:2289–e22952. https://doi.org/10.1016/j.jamda.2021.03.031
doi: 10.1016/j.jamda.2021.03.031
pubmed: 33957132
Kwok JYY, Kwan JCY, Auyeung M, Mok VCT, Lau CKY, Choi KC, et al. Effects of Mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson Disease: a Randomized Clinical Trial. JAMA Neurol. 2019;76:755–63. https://doi.org/10.1001/jamaneurol.2019.0534
doi: 10.1001/jamaneurol.2019.0534
pubmed: 30958514
pmcid: 6583059
Ban M, Yue X, Dou P, Zhang P. The effects of yoga on patients with Parkinson’s Disease: a Meta-analysis of Randomized controlled trials. Behav Neurol. 2021;2021:5582488. https://doi.org/10.1155/2021/5582488
doi: 10.1155/2021/5582488
pubmed: 34285724
pmcid: 8275425
Fan J-Q, Lu W-J, Tan W-Q, Liu X, Wang Y-T, Wang N-B, et al. Effectiveness of acupuncture for anxiety among patients with Parkinson Disease: a Randomized Clinical Trial. JAMA Netw Open. 2022;5:e2232133. https://doi.org/10.1001/jamanetworkopen.2022.32133
doi: 10.1001/jamanetworkopen.2022.32133
pubmed: 36129711
pmcid: 9494193